Achieve Life Sciences (ACHV) Non-Current Deffered Revenue (2010 - 2011)
Achieve Life Sciences (ACHV) recorded quarterly Non-Current Deffered Revenue of $9.0 million in Q3 2011, down 8.41% on a QoQ basis from $9.9 million in Q2 2011.
Achieve Life Sciences (ACHV) Non-Current Deffered Revenue (2010 - 2011) Analysis & Trends
Achieve Life Sciences has disclosed Non-Current Deffered Revenue across 2 years of filings, most recently posting $9.0 million for Q3 2011.
- Quarterly Non-Current Deffered Revenue changed N/A year-over-year to $9.0 million in Q3 2011, while the trailing twelve-month figure through Sep 2011 was $9.0 million (changed N/A YoY) and the FY2010 annual result came in at $11.6 million, changed N/A from the prior year.
- Non-Current Deffered Revenue slipped to $9.0 million in Q3 2011, from $9.9 million in the prior quarter.
- Over five years, Non-Current Deffered Revenue peaked at $11.6 million in Q4 2010 and troughed at $9.0 million in Q3 2011.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Achieve Life Sciences | 93.71 Mn | 63.22 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2011 | 9.04 Mn |
| Jun 30, 2011 | 9.87 Mn |
| Dec 31, 2010 | 11.62 Mn |